Atea Pharmaceuticals Inc
AVIR
Get informed when a big investor buys or sells
+ FollowMarket Cap$399.34M
Close$
$1.16
75.2% downside
Current Fair Value
75.2% downsideOvervalued by 75.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $399.34 Million |
|---|---|
| Enterprise Value | $320.65 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.94 |
| Beta | 0.32 |
| Outstanding Shares | 79,198,204 |
Return
| Return on Equity | -72.53% |
|---|---|
| Return on Assets | -63.47% |
| Return on Invested Capital | -81.24% |
Valuation & Multiples
| P/E Ratio | -2.36 |
|---|---|
| PEG | -7.26 |
| Price to Sales | - |
| Price to Book Ratio | 2.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.69 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
$22.42 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$33.03 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 73.73% |
|---|---|
| Total Invested | $43,046▼ 99.99% |
| Investors Holding | 3▼ 126.00% |
ESG Score
No data
About Atea Pharmaceuticals Inc
39 employeesAtea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding of...